Small molecular inhibitors for KRAS-mutant cancers

Small molecular inhibitors for KRAS-mutant cancers

Three rat sarcoma (RAS) gene isoforms, KRAS, NRAS, and HRAS, constitute the most mutated family of small GTPases in cancer. While the development of targeted immunotherapies has led to a substantial improvement in the overall survival of patients with non-KRAS-mutant cancer, patients with RAS-mutant...

Full description

Bibliographic Details
Main Authors: Xuan Wu, Wenping Song, Cheng Cheng, Ziyang Liu, Xiang Li, Yu Cui, Yao Gao, Ding Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Immunology
Subjects:
RAS mutation
different isoform
RAS inhibitor
immunotherapy
combination strategy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1223433/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1223433/full

Similar Items